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Abstract
Background: Effective postoperative pain management is essential for the rehabilitation of the surgical patient. No
‘gold standard’ exists after total hip arthroplasty (THA) and combinations of different nonopioid medications are
used with virtually no evidence for additional analgesic efficacy compared to monotherapy. The objective of this
trial is to investigate the analgesic effects and safety of paracetamol and ibuprofen alone and in combination in
different dosages after THA.
Methods: PANSAID is a placebo-controlled, parallel four-group, multicentre trial with centralised computer-
generated allocation sequence and allocation concealment and with varying block size and stratification by site.
Blinding of assessor, investigator, caregivers, patients and statisticians. Patients are randomised to four groups: (A)
paracetamol 1 g × 4 and ibuprofen 400 mg × 4, (B) paracetamol 1 g × 4 and placebo, (C) placebo and ibuprofen
400 mg × 4 and (D) paracetamol 0.5 g × 4 and ibuprofen 200 mg. The two co-primary outcomes are 24-h
consumption of morphine and number of patients with one or more serious adverse events within 90 days after
surgery. Secondary outcomes are pain scores during mobilisation and at rest at 6 and 24 h postoperatively, and
number of patients with one or more adverse events within 24 h postoperatively. Inclusion criteria are patients
scheduled for unilateral, primary THA; age above 18 years; ASA status 1–3; BMI >18 and <40 kg/m2; women must
not be pregnant; and provision of informed consent. Exclusion criteria are patients who cannot cooperate with the
trial; participation in another trial; patients who cannot understand/speak Danish; daily use of strong opioids; allergy
against trial medication; contraindications against ibuprofen; alcohol and/or drug abuse. A total of 556 eligible
patients are needed to detect a difference of 10 mg morphine i.v. the first 24 h postoperatively with a standard
deviation of 20 mg and a family wise type 1 error rate of 0.025 (two-sided) and a type 2 error rate of 0.10 for the
six possible comparisons of the four intervention groups.
Discussion: We started recruiting patients in December 2015 and expect to finish in September 2017. Data analysis
will be from September 2017 to October 2017 and manuscript submission ultimo 2017.
Trial registration: EudraCT: 2015-002239-16 (12/8-15); ClinicalTrials.gov: NCT02571361. Registered on 7
October 2015.
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Background
Effective postoperative pain management that promotes
early mobilisation, fluid and food intake, and the re-
sumptions of normal activities is essential for the well-
being and rehabilitation of the surgical patient [1] and is
a core component in enhanced recovery after surgery
programmes [2, 3]. In daily clinical practice, patients are
most often treated with different combinations of
nonopioid drugs and analgesic methods (‘multimodal
analgesia’) to achieve better analgesic effects and
lower opioid requirements including their well-known
adverse effects.
The medical literature on postoperative multimodal
analgesia is, however, heterogenic and characterised
by typically small studies using a variety of different
combinations and techniques, and most often with
short follow-up times that lower the probability of de-
tecting relevant adverse effects. Consequently, most
combinations of analgesics are not well-documented
[4] and, therefore, it is a significant risk that patients’
pain is either treated insufficiently, or that patients
receive combinations of analgesics without additive ef-
fects but with an increased risk of adverse effects [5].
It is documented that lack of systematic reporting of
adverse events (AE) is frequent [5], yet, the rate of
serious adverse events (SAEs) in a mixed orthopaedic
population was found to be as high as 6.2% in a re-
cent retrospective study [6].
The two most common drugs used as basic nono-
pioid analgesics after surgery are paracetamol and
nonsteroidal anti-inflammatory drugs (NSAIDs). These
drugs have a proven analgesic and morphine-sparing
effect when administered individually [7, 8], whereas
evidence of an additive and improved analgesic effect
of their combination is virtually absent [4]. Further-
more, particularly the NSAIDs are associated with a
number of potential adverse effects, e.g. gastrointes-
tinal bleeding [9, 10], thromboembolic events [11, 12],
impaired renal function [13], anastomotic leakage
[14–17] and delayed bone-healing [18]. It has further
been suggested that no safe treatment window exists,
even for short periods of NSAID therapy, in patients
with cardiovascular disease [19].
As stated above, the scientific evidence of a beneficial
effect of the combined use of paracetamol and NSAIDs
is limited. It is primarily based on two recent reviews: a
systematic, qualitative review of 21 trials including a
wide range of different pain models [20] and a Cochrane
review with meta-analysis of three trials of dental surgi-
cal extraction [7] (Table 1).
The review by Ong et al. [20] included 1909 pa-
tients and, based on the available data, it concludes
that it was not possible to perform meta-analysis.
They conclude that the combination of paracetamol
and NSAIDs may provide superior analgesia com-
pared to either drug alone. The review is limited by a
qualitative approach including a wide range of acute
pain models, and pooling of both minor and major
surgical procedures in the analyses. Overall, 85% of
trials comparing paracetamol and a NSAID versus
paracetamol alone and 67% of trials comparing para-
cetamol and a NSAID versus a NSAID alone, pro-
vided more effective pain relief of the combination
compared to single drugs.
The Cochrane review with meta-analysis [7] included
1647 patients, and investigated the combined effects of
paracetamol and NSAIDs on established pain after den-
tal surgery, with surgical removal of at least three im-
pacted third molars. It was concluded that combination
therapy (both ibuprofen 200 mg/paracetamol 500 mg and
ibuprofen 400 mg/paracetamol 1000 mg) is more effective
than placebo (Number Needed to Treat ((NNT) 1.6 and
NNT 1.5, respectively) and that ibuprofen 400 mg/para-
cetamol 1000 mg is more effective than ibuprofen alone
(NNT 5.4). No comparison of combination therapy
versus paracetamol alone was included in this meta-
Table 1 The most recent systematic reviews of combined paracetamol and a nonsteroidal anti-inflammatory drug (NSAID) versus
paracetamol or a NSAID alone in postoperative pain management, NNT Number Needed to Treat
Study Intervention Number of
patients
Surgery Pain Opioid Adverse
events
Derry
2013 [7]
Paracetamol
and ibuprofen
vs. ibuprofen
1647
(3 trials)
Extraction
of at least 3
impacted
third molars
Ibuprofen 200 mg and paracetamol
500 mg vs. placebo: NNT 1.6 (1.5–1.8)
Ibuprofen 400 mg and paracetamol
1000 mg vs. placebo: NNT 1.5 (1.4–1.7)
Ibuprofen 400 mg and paracetamol 1000 mg
vs. ibuprofen 400 mg: NNT 5.4 (3.5–12.2)
Time to rescue medication:
Ibuprofen 200 mg and
paracetamol 500 mg: 7.6 h
Ibuprofen 400 mg and
paracetamol 1000 mg:
8.3 h Placebo: 1.7 h
No
information
Ong
2010 [20]
Combinations of
paracetamol and
various NSAIDs vs.
1 of these drugs
1909
(21 trials)
Mixed
surgical
populations
Paracetamol and NSAID vs. paracetamol: 85%
of studies showed that the combination had
better analgesic properties than paracetamol
alone Paracetamol and NSAID vs. NSAID: 64%
of these studies showed that the combination
had better analgesic properties than NSAID alone
Reduction in opioid
consumption is not
quantified in a
combined measure
No
systematic
information
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analysis. The trials included only investigated rela-
tively healthy and young adults.
Total hip arthroplasty (THA) is a common proced-
ure and may be associated with moderate to intense
postoperative pain. A large number of different treat-
ment options have been investigated for pain
following THA [21, 22] including opioids, corticoste-
roids, NSAIDs, paracetamol and gabapentinoids and
various neuroaxial and peripheral nerve blocks.
However, no established ‘gold standard’ for pain
management after THA can be presented [21]. The
most recent recommendation from postoppain.org
includes paracetamol, NSAIDs (either COX-2 select-
ive or mixed type) and opioids as rescue [23]. This
trial will potentially provide valuable information
about the optimal basic nonopioid combination regi-
men for pain management after THA.
In the present trial, we have chosen THA as the
analgesic model for investigating benefit and harm of
short-term treatment of paracetamol and NSAIDs in
the trial: PANSAID – PAracetamol and NSAID in
combination: a randomised, blinded, parallel four-
group clinical trial.
Aims
The aim of the PANSAID trial, is to investigate the anal-
gesic effects and safety of paracetamol and ibuprofen
and their combination in different dosages after THA.
Methods/design
PANSAID is a randomised multicentre trial with a
central computer-generated allocation sequence,
concealed allocation, blinding of assessors, investiga-
tors, caregivers, patients and statisticians in patients
having an elective total hip arthroplasty (Fig. 1).
Patients will be randomised with varying block size
and stratified according to site for treatment groups
receiving either paracetamol and ibuprofen, paraceta-
mol and placebo, placebo and ibuprofen or paraceta-
mol and ibuprofen in a reduced dosage.
Hypothesis
We hypothesise that the combination of paracetamol
and ibuprofen is more effective than each drug alone
and will reduce opioid consumption and/or pain
levels. In addition, we hypothesise that a combination
of lower doses of paracetamol and ibuprofen will
Fig. 1 PANSAID flowchart
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demonstrate analgesic efficacy comparable to higher
doses of each drug alone, and will reduce the risk of
adverse effects per se.
Analgesic interventions
NSAIDs have anti-inflammatory, antipyretic and anal-
gesic properties and act by a reversible inhibition of the
cyclooxygenase (COX) enzyme, which mediates the syn-
thesis of prostaglandins and thromboxane A2. COX ex-
ists (primarily) in two isoforms, COX-1 and COX-2, and
nonselective NSAIDs inhibit both isoforms (in varying
degrees), while COX-2-selective NSAIDs inhibit mostly
COX-2 [24, 25]. There are a number of potential adverse
effects of NSAID treatment, including increased risk of
cardiovascular events [11], gastrointestinal bleeding [9],
ulcers [10], renal impairment [26], anastomotic leakage
[14–17] and possible impaired bone-healing [18]. Fur-
thermore, although the cardiovascular and gastrointes-
tinal adverse effects are not well-characterised, there is
some evidence that none of the NSAIDs are completely
safe, especially for longer-term use [11, 27]. In the exist-
ing medical literature, most of these adverse effects are
limited in description for short-term use in the peri-
operative setting, and a number of them may be related
to NSAIDs with high COX-2 selectivity, e.g. diclofenac.
The European Medicines Agency has recognised an in-
creased cardiovascular risk in treatment with high-dose
ibuprofen (more than 2400 mg per day) [28]. For post-
operative pain treatment; it may, therefore, be safest to
choose nonselective NSAIDs, like ibuprofen and na-
proxen, and in lowest effective dose and for as short a
duration as possible, when NSAID treatment is needed.
Paracetamol has antipyretic and analgesic effects and
is generally recommended as the first-line drug in nono-
pioid analgesic therapies including postoperative pain
management. Its mode of action is still controversial and
not yet fully understood. There may be a central effect
via cannabinoid and vanilloid receptors and/or descend-
ing serotonergic pathways and, furthermore, a peripheral
and central COX-inhibition has been proposed [29]. Al-
though paracetamol is considered to have few adverse
effects within the recommended dose range, liver failure
is a known adverse effect in the setting of overdose or in
specific patient populations (malnutrition, excess alcohol
intake, etc.) [29].
Paracetamol and ibuprofen are available as ‘over-the-
counter’ medications in many countries and are standard
analgesic drugs used for postoperative pain treatment. In
this trial, paracetamol is administered in total doses of
2000 mg and 4000 mg, and ibuprofen in doses of
800 mg and 1600 mg per day. For both paracetamol and
ibuprofen these doses are within the range of nor-
mally recommended and used postoperative doses
and regimens.
Inclusion criteria
Patients must meet all the following criteria to be suit-
able for inclusion in the trial:
 Scheduled for unilateral, primary THA
 Aged over 18 years
 Have an American Society of Anesthesiologists
(ASA) physical status classification score 1–3.
 Have a Body Mass Index (BMI) >18 and <40 kg/m2
 Women in the fertile age must have a negative
urinary human chorionic gonadotropin (HCG)
pregnancy test
 Patients must give written informed consent for
participation in the trial after having fully understood
the contents of the protocol and any restrictions
Exclusion criteria
Patients who meet one or more of the following criteria
are not suitable for inclusion in this trial:
 Patients who cannot cooperate with the trial (e.g.
use of the PCA-pump, understand the Visual
Analogue Scale (VAS) ruler, etc.)
 Concomitant participation in another trial
 Patients who cannot understand or speak Danish
 Daily use of strong opioids (tramadol and codeine
are accepted)
 Patients with allergy to the medicines used in
the trial
 Contraindications against NSAIDs and paracetamol,
e.g. known heart failure, liver failure, renal failure
(estimated glomerular filtration rate (eGRF) <60 ml/
kg/1.73 m2), thrombocytopenia (<100 mia/L) or
previous gastric ulcer
 Patients with alcohol and/or drug abuse – based
on the investigator’s judgement
Randomisation
Patients will be randomised to four groups at a 1:1:1:1
ratio with block randomisation of varying size and strati-
fied by site. Copenhagen Trial Unit (CTU), Rigshospita-
let, Denmark, provides a website for central computer
randomisation. Each patient entering the trial will be
given a unique randomisation number and a corre-
sponding ‘trial medicine number’.
Outcome measures
Co-primary outcomes
 Total need for morphine the first 24 h
postoperatively administered as both patient-
controlled analgesia (PCA) and supplemental
morphine administered at the postanaesthesia
unit the first hour postoperatively
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 Serious adverse events, including death, within
90 days after surgery defined as a SAE (according to
International Conference on Harmonisation-Good
Clinical Practice (ICH-GCP) guidelines) except
‘prolongation of hospitalisation’
Secondary outcomes
 Pain scores (VAS) with active 30° flexion of the hip
at 6 and 24 h postoperatively
 Pain scores at rest (VAS) at 6 and 24 h
postoperatively
 Number of patients with one or more AE in the
intervention period (0–24 h)
Exploratory outcomes
 Level of nausea at 6 and 24 h postoperatively
 Number of vomiting episodes (0–24 h) measured in
the periods 0–6 and 6–24 h postoperatively
 Consumption of ondansetron in the period 0–24 h
postoperatively
 Level of sedation at 6 and 24 h postoperatively
 Level of dizziness at 6 and 24 h postoperatively
 Blood loss during the surgical procedure
(intraoperatively)
 Days alive and outside hospital within 90 days after
surgery
Methods of measurements
The total dose of morphine (mg) in the period 0–24 h
postoperatively, including PCA-morphine and nurse-
administered supplemental morphine (bolus 2 mg) on
patient request for the first postoperative hour, is re-
corded. Patients’ pain is recorded on a VAS of 100 mm,
where 0 = no pain and 100 = worst possible pain. Pain is
recorded at rest, and during 30° active flexion of the hip
and at rest.
Nausea, sedation and dizziness are recorded on a ver-
bal scale (none, mild, moderate, severe). The number of
productive vomiting events (volume estimated over
10 ml) is recorded corresponding to the periods 0–6 and
6–24 h postoperatively by interview with the patient.
Total use of ondansetron (mg) 0–24 h postoperatively is
recorded. Patient-reported adverse effects are recorded,
including gastrointestinal disturbances, neurological dis-
turbances and elevated serum creatinine.
Ninety-day mortality rate is recorded from the civil
registration system through Statistics Denmark. Serious
adverse events (SAEs) are recorded from the Danish Na-
tional Patient Registry. SAEs are defined as modified
SAEs according to the ICH-GCP guidelines excluding
‘prolongation of hospitalisation’, as we recognise that it
will be impossible to adjudicate such events.
Analgesic medication (paracetamol and NSAIDs) and
need for medical attention from discharge to the end of
trial period (90 days) are recorded from the patient
questionnaire. At sites where a 3-month clinical control
visit is part of the routine follow-up after THA the
questionnaire is returned. If no such visit is routine the
investigator at that site will telephone the patient or con-
tact the patient by mail.
Trial intervention
The trial period is from randomisation to 90 days post-
operative. The intervention period is from randomisa-
tion to 24 h postoperative.
Treatment A
Paracetamol 1000 mg + ibuprofen 400 mg given per os
starting 1 h before surgery and administered every 6 h
postoperatively (±1 h), i.e. a total of four times the first
postoperative day.
Treatment B
Paracetamol 1000 mg + placebo given per os starting 1 h
before surgery and administered every 6 h postopera-
tively (±1 h), i.e. a total of four times the first postopera-
tive day.
Treatment C
Placebo + ibuprofen 400 mg given per os starting 1 h
before surgery and administered every 6 h postopera-
tively (±1 h), i.e. a total of four times the first postop-
erative day.
Treatment D
Paracetamol 500 mg + ibuprofen 200 mg given per os
starting 1 h before surgery and administered every 6 h
postoperatively (±1 h), i.e. a total of four times the first
postoperative day.
Concomitant medication/treatment
Standard premedication:
 None
Standard anaesthesia:
 For spinal anaesthesia bupivacaine 0.5% plain,
10–15 mg is used and no opioids are added. If
sedation is needed propofol infusion is used
For general anaesthesia propofol infusion and remifen-
tanil infusion are used as needed. If needed, sevoflurane-
based anaesthesia will alternatively be allowed and
recorded.
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 Fifteen minutes before end of surgery sufentanil 0.3
mcg/kg intravenously (i.v.) is given to patients under
general anaesthesia
Standard postoperative pain and nausea management:
 PCA-morphine, bolus 2 mg, lockout time 10 min.
Mixture: morphine 1 mg/ml.
 If there is a need for morphine in addition to the
PCA pump in the first 1 h postoperatively at the
postanaesthesia care unit, additional bolus doses
of 2 mg morphine i.v. can be given on request by
the patient
 Ondansetron 4 mg i.v. is administered at the first
indication of moderate-severe nausea and may then
be supplemented with 1 mg i.v. Maximal total dose
allowed is 8 mg over the first postoperative day
Pain treatment at the end of the intervention period
will follow departmental guidelines.
Analgesic medications other than the PCA-morphine,
including other opioids, chlorzoxazone, antidepressants,
steroids and gabapentinoids (gabapentin or pregabalin),
are not permitted during the intervention period. Gaba-
pentinoids and antidepressants are only permitted if the
patient continues an already instituted treatment from
before surgery.
All nonanalgesic medications are permitted at the dis-
cretion of the attending physician.
Blinding
The study medication will be masked by the pharmacy.
Participants, those administrating the intervention, other
caregivers, outcome assessors, data managers, statisti-
cians and investigators drawing conclusions will be
blinded to the intervention. The experimental medicine
will be packed and labelled by the Capital Region Phar-
macy in accordance with Good Manufacturing Practice
(GMP) hereof. The trial medication is packed in one box
per participant containing all medication for the inter-
vention period. CTU retains the nonblinded list of the
allocation sequence list stratified for sites, which will
only be revealed for the investigators when the data has
been analysed and abstracts [30] and conclusions cover-
ing the different possibilities for interpreting the trial re-
sults have been agreed upon by the Steering Committee/
investigators. The investigators, as well as Jørn Wetter-
slev from CTU, have no access to the randomisation list.
Safety
Adverse events (AE), adverse reactions (AR), serious ad-
verse events (SAEs), serious adverse reactions (SARs)
and suspected unexpected serious adverse reactions
(SUSARs) will be recorded in the intervention period
and will be reported to the relevant authorities according
to guidelines from ICH-GCP and the Danish Medicines
Agency.
Participant withdrawal
Discontinuation of individual participants
If a SAE (according to the IHC-GCP definition) occurs
in the intervention period (0–24 h postoperatively) and
the investigator, after consultation with either principal
investigator or sponsor, finds it infeasible for the patient
to continue the trial, the medication will be discontinued
and the participant will be asked whether we may still
record data including follow-up data.
The blinding may only be broken if the continued
treatment of the patient requires knowledge of the ran-
domisation code. This can be done by the investigator
without restrictions. Breaking of the code is done by
contacting CTU by telephone.
Participant withdrawal
A patient who has not completed the trial is a patient in-
cluded in the trial, i.e. one who has given informed con-
sent, been randomised but withdraws the consent and
does not allow for continued data recording after dis-
continuing the trial medications.
If a patient does not complete the trial an account is
given as to whether and how this participant is followed
in the trial – this also applies to dropouts – as well as
what data has been collected from these participants.
The patient will be asked if the withdrawal is only for
the intervention/treatment and if they allow for further
data registration or if withdrawal is also for any further
data registration.
Statistics
Sample size estimation
Due to six possible comparisons and a wish to limit the
maximal family wise error rate to 0.025 (two-sided) for
each of the co-primary outcomes, for a power of 90% we
will need to randomise 556 patients (139 in each inter-
vention group) to detect or to discard a minimal clinic-
ally relevant difference (10 mg) in 24-h morphine
consumption with a standard deviation of 20 mg over
24 h. However, for the coprimary outcome of patients
with one or more SAE we will collate events pending
the use of ibuprofen or not corresponding to one com-
parison of 417 versus 139 patients. This comparison ad-
dresses possible harm due to the use of ibuprofen versus
no use; a two-sided maximal type 1 error rate of 0.025
rendering a power of 80% to detect or discard an in-
crease in the number of patients with one or more SAE
from 10% to 20% will be used.
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Statistical methods
The trial will be completed when 556 patients are in-
cluded in the trial. The primary analysis will be a modi-
fied (excluding patients randomised but not operated)
intention-to-treat comparing the co-primary outcome of
opioid consumption between the four groups and the
co-primary outcome of patients with one or more SAE
between collated groups randomised to ibuprofen versus
the group not receiving ibuprofen. If there are more
than 5% missing data or patients lost to follow-up and
Little’s test is statistically significant we will use multiple
imputations (MI) to impute missing data [31]. Complete
case analysis will be performed as well but the results of
the analyses using MI-imputed datasets will be consid-
ered the primary result of the trial. The primary analysis
of the continuous outcome of morphine consumption
within 24 h will be nonparametric pair-wise comparisons
between the median consumption of morphine between
the four groups (six analyses) stratified for sites with the
van Elteren test [32]. If possible 99.6% and 95% confi-
dence intervals for the difference in medians will be pro-
vided by boot-strapping.
Per-protocol analyses excluding patients with major
protocol violations will also be performed. Major proto-
col violations are defined below. Per-protocol analyses
regarding SAEs and other safety variables will, however,
include patients with major protocol violation definition
number 3 (below).
Major protocol violations will be defined as:
1. Patients who did not get any of the dosages of the
randomised allocated trial treatment
2. Patients withdrawing from the trial intervention but
allowing the use of registered data
3. Patients undergoing surgery (besides the elective
THA) or a procedure in the intervention period that
requires anaesthesia or sedation and/or analgesia
The evaluability assessment of each patient in the stat-
istical analyses will be performed before the code is
broken. Excluded patients and missing, unused or false
data will be described. Data will be stored and evaluation
and statistical analysis will be made by a statistician
blinded for the interventions, where patient anonymity
will be preserved and local data legislation will be
observed.
Any change to the statistical plan will be accounted
for by publication. A detailed statistical analysis plan will
be published.
Data collection
All data will be entered into an electronic Case Report
Form (eCRF) created and maintained by CTU (Fig. 2).
The eCRF will form the basis for the electronic database.
Data will be collected directly from the patients by trial
investigators or clinical personnel educated and moni-
tored by trial investigators and from the electronic an-
aesthesia chart, the electronic patients chart, the civil
registration system through Statistics Denmark, and the
Danish National Patient Registry. All data will be han-
dled according to The Danish Data Protection agency
and local original data (e.g. Informed Consent Forms)
and records will be stored at trials sites for 5 years after
the completion of the study. The study database will be
anonymised and made publically accessible 18 months
following publication of the study.
Monitoring
The trial will be externally monitored by the University
of Copenhagen Good Clinical Practice (GCP) Unit ac-
cording to the latest legislation.
Ethical consideration
The trial will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki and in compliance
with the protocol approved by the competent authority
and Ethics Committee, and according to GCP standards
[33]. No deviation from the protocol will be imple-
mented without the prior review and approval of the
regulatory authorities except where it may be neces-
sary to eliminate an immediate hazard to the trial
participants.
Data analysis and publication
Prior to breaking of the randomisation code an inde-
pendent statistician will perform the data analysis ac-
cording to a detailed statistical analysis plan. Based on
the masked result the Steering Committee will agree
upon abstracts covering all possible combinations and
then the blinding will be broken. The final manuscript
will contain the correct pre-made abstract. The protocol
followed the Standard Protocol Items: Recommenda-
tions for Interventional trials (Additional file 1) [34] and
the manuscript will follow Consolidated Standards Of
reporting of Randomised Trials (CONSORT Statement)
[35]. Authorship will be granted following the guidelines
from the International Committee of Medical Journal
Editors (ICMJE) [36]. Funding sources will have no in-
fluences on the interpretation of data.
The full, anonymised dataset will be published no
longer than 18 months after completion of the trial.
The trial is registered at clinicaltrials.gov with identi-
fier: NCT02571361.
Substudies
We preplan the following substudies:
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1. A reanalysis of benefit outcomes (pain and opioid
consumption) with respect to the following
subgroups: sex, age, ASA-score, type of surgery
(uncemented, cemented or hybrid), surgical site
(posterior approach versus anterolateral approach)
and anaesthetic technique (general anaesthesia
versus spinal anaesthesia)
2. A reanalysis of harm (AEs and opioid-related side ef-
fects) with respect to the following groups sex, age,
ASA-score, anaesthetic technique (general anaesthe-
sia versus spinal anaesthesia) and opioid consump-
tion (in the intervention period)
3. Longer follow-up than the specified 90 days
(1 year)
4. An analysis of the association between VAS scores
and opioid consumption
5. Time-to-event analyses regarding use of PCA-
morphine
Fig. 2 Screenshot of the electronic Case Report Form (eCRF)
Fig. 3 Screenshot of the trial homepage, www.pansaid.dk
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6. An analysis of the association between preoperative
analgesic use and pain/morphine consumption
7. An analysis of the individual patients: how many will
achieve ‘no worse than mild pain’ (NRS <3)
More substudies may be performed post hoc and they
will be clearly identified as such.
Timeline
2015: application for approval from the Danish Medi-
cines Agency, the Ethics Committee and the Danish
Data Registration Agency. Development of an eCRF and
randomisation website
2015–2017: inclusion of patients
2018: data analysis, writing and submission of the
manuscript
Discussion
PANSAID will provide the first, large, high-quality data
regarding the combination of paracetamol and ibuprofen
used in a surgical setting. We expect this trial to supply
a significant contribution to a systematic and evidence-
based approach towards nonopioid multimodal analgesic
regimens for postsurgical treatment in a broader
context.
Trial status
Currently, more than 200 patients have been enrolled in
the trial. The trial status can be seen at the trial website
www.pansaid.dk (Fig. 3). We expect the enrolment
period to end in September 2017.
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